Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.
The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.
New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.
Philippe Genereux, MD, medical director of the Structural Heart Disease Program at Morristown Medical Center, discusses the use of transcatheter aortic valve replacement (TAVR) procedures in patients with severe, calcific aortic stenosis who are asymptomatic.
A new meta-analysis of 28 different studies confirmed that robotic-assisted radical nephrectomy with IVC thrombectomy is a safe treatment option for kidney cancer.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
![When kidney cancer invades a patient’s inferior vena cava (IVC), robotic-assisted radical nephrectomy with IVC thrombectomy is a safe and effective alternative to open surgery, according to a new meta-analysis published in the Journal of Urology.[1]](/sites/default/files/styles/240x220/public/2022-08/screen_shot_2022-08-22_at_11.09.53_am.png.webp?itok=hS7Q-65H)